3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Toxicokinetics, dose–response, and risk assessment of nanomaterials: Methodology, challenges, and future perspectives

      1 , 2 , 3 , 4 , 1 , 2
      WIREs Nanomedicine and Nanobiotechnology
      Wiley

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d2874566e101">The rapid growth of nanomaterial applications has raised safety concerns for human health. A number of studies have been conducted to assess the toxicokinetics, toxicology, dose-response, and risk assessment of different nanomaterials using in vitro and in vivo animal and human models. However, current studies cannot meet the demand for efficient assessment of toxicokinetics, dose-response relationships, or the toxicological risk arising from the rapidly increasing number of newly synthesized nanomaterials. In this article, we review the methods for conducting toxicokinetics, hazard identification, dose-response, exposure, and risk assessment studies of nanomaterials, identify the knowledge gaps, and discuss the challenges remaining. We provide the rationale behind the appropriate design of nanomaterial plasma toxicokinetic and tissue distribution studies, including caveats on the interpretation and correlation of in vitro and in vivo toxicology studies. The potential of using physiologically based pharmacokinetic (PBPK) models to extrapolate toxicokinetic and toxicity findings from in vitro to in vivo and from animals to humans is discussed, and the knowledge gaps of PBPK modeling for nanomaterials are identified. While challenges still exist, there has been progress in the toxicokinetics, hazard identification, and risk assessment of nanomaterials in the past two decades. Recent advancements in the field are highlighted with relevant examples. We also share latest guidelines as well as our perspectives on future studies needed to characterize the toxicokinetics, toxicity, and dose-response relationship in support of nanomaterial risk assessment. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine &gt; Toxicology of Nanomaterials Toxicology and Regulatory Issues in Nanomedicine &gt; Regulatory and Policy Issues in Nanomedicine. </p>

          Related collections

          Author and article information

          Contributors
          Journal
          WIREs Nanomedicine and Nanobiotechnology
          WIREs Nanomed Nanobiotechnol
          Wiley
          1939-5116
          1939-0041
          November 2022
          November 23 2022
          November 2022
          : 14
          : 6
          Affiliations
          [1 ]Department of Environmental and Global Health College of Public Health and Health Professions, University of Florida Gainesville Florida USA
          [2 ]Center for Environmental and Human Toxicology University of Florida Gainesville Florida USA
          [3 ]The 1Data Consortium Kansas State University Olathe Kansas USA
          [4 ]Center for Chemical Toxicology Research and Pharmacokinetics, Department of Population Health and Pathobiology College of Veterinary Medicine, North Carolina State University Raleigh North Carolina USA
          Article
          10.1002/wnan.1808
          e56d88d9-8286-46ee-9583-52c3d55f1dfd
          © 2022

          http://onlinelibrary.wiley.com/termsAndConditions#vor

          http://doi.wiley.com/10.1002/tdm_license_1.1

          History

          Comments

          Comment on this article